New modified citrus pectin slows cancer progression and stops cancer cells in their tracks
Study Shows New Modified Citrus Pectin Works as Well as Chemo Without Toxicity and Improves Quality of Life in Advanced Disease. Better Health Publishing announced today that many people with cancer could be helped by a new form of Modified Citrus Pectin (MCP) that may work as well as chemotherapy in advanced disease stages; yet without the dangerous toxicity. These published findings of new capabilities for MCP have the potential to revolutionize integrative cancer healthcare.
Previous research with MCP has shown it to be effective in slowing the progression, metastasis and angiogenesis of several types of cancer. Now with further improvement in the modification process, more of the effective substance can be utilized by the body. The first human study described below was done with patients with late stage, breast, prostate, colorectal, kidney, pleural or lung, cervix/uterine cancer, liver, pharynx, pancreatic, stomach, melanoma and bile duct cancers.
This landmark clinical trial was published in the peer-reviewed journal Clinical Medicine: Oncology, where it showed a significant improvement of quality of life and stabilization of disease for patients with advanced solid tumors. The results of the landmark advanced tumor study clearly demonstrate MCP's enhanced capabilities.
"This is a very important breakthrough destined to help a lot of people," said Dr. Isaac Eliaz, a prominent doctor of Integrative Medicine and MCP researcher. "MCP may have the benefits similar to chemotherapy in advanced cancers, but without the side effects. This study sheds additional light on the potential benefits of MCP in cancer prevention and treatment.
A background report on the development of MCP in integrative cancer healthcare is available through Better Health Publishing at the following url:
www.betterhealthpublishing.org/mcpreport
MCP, a natural substance modified from the peel of citrus fruit has been used during the past decade in integrative cancer therapy to help keep aberrant cells from clustering and blocking the formation of blood vessel attachment. The absorption into the blood stream is based on the size and weight of its molecules.
MCP molecules bind to receptors on cancerous cells, preventing these cells from attaching to healthy tissue and blocking the formation of blood vessels to feed the cancerous cells. Once this has occurred, the cancer cells starve and die or are eliminated by the immune system.
In the past, the enzymatic modification process produced too much total breakdown of the pectin molecules when it tried to achieve the effective low molecular weight absorbable chains. The new MCP also goes through an enzymatic process that reduces the pectins molecular size and modifies it to better control the amount of total breakdown of the citrus pectin. These new developments led to an improved MCP, lower in weight, which allows it to be more systemic, circulating through the blood stream and allowing the body to absorb more of the effective molecules.
Treatment and Scientific Data of Study:
The treatment in the advanced tumor and previous studies consisted of the oral intake of five grams of MCP three times a day. One cycle of therapy was defined as four weeks of treatment. Objectives were clinical benefit (pain, functional performance, weight change), safety, tumor response (RESIST criteria) and quality of life.
The results proved very exciting. Forty-nine patients (between 36 and 82 years old) with various advanced solid tumors were enrolled. Twenty-nine patients were evaluated for clinical benefit after two cycles of treatment. All patients tolerated the therapy well without any adverse effects. The results also demonstrated that after two cycles of oral intake of MCP, 6/29, (20.7%) had an overall clinical benefit with a stabilization or improvement of life quality. On intent to treat basis 11/49 patients (22.5%) showed a stable disease after two cycles and 12.3% had a SD for more than 24 weeks. One patient with advanced and hormonal resistant prostate cancer had a 50% decrease in PSA with significant improvement in his quality of life. Most of the patients had improvements in their life quality as reflected in the Karnofsky scores.
The MCP used in the advanced tumor study is now commercially available in the US. It's called PectaSol-C and distributed by EcoNugenics, Santa Rosa, CA.
About Better Health Publishing:
Better Health Publishing, founded by Isaac Eliaz, M.D. is a publishing house that focuses on the publication of key works promoting health and wellness. The staff at Better Health Publishing believes that a natural and efficacious lifestyle is the cornerstone of a return to healthy and sustainable society. The works published by BHP strive to promote this concept and disseminate to the public a healthier choice. For more information on Dr. Eliaz, log onto
www.dreliaz.org. For a free report on MCP log onto
www.betterhealthpublishing.org/mcpreport
Publication date: 6/4/2008
http://www.freshplaza.com/news_detail.asp?id=22985 
